Detalhe da pesquisa
1.
Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.
Crit Care
; 28(1): 73, 2024 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38475786
2.
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia.
Cytokine
; 162: 156111, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529030
3.
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.
EClinicalMedicine
; 56: 101785, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36590789
4.
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
Cell Rep Med
; 3(3): 100560, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35474750
5.
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
J Hypertens
; 39(4): 749-758, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186325
6.
Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Am J Hypertens
; 34(4): 404-413, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33277990
7.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Nat Med
; 27(10): 1752-1760, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480127
8.
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Nat Med
; 27(10): 1850, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625750